NASDAQ:GRAL - Nasdaq - US3847471014 - Common Stock - Currency: USD
Overall GRAL gets a fundamental rating of 4 out of 10. We evaluated GRAL against 566 industry peers in the Biotechnology industry. GRAL has a great financial health rating, but its profitability evaluates not so good. GRAL is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -67.94% | ||
ROE | -80.97% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 44.48% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -3.59 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 10.66 | ||
Quick Ratio | 10.66 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:GRAL (5/1/2025, 12:39:46 PM)
32.96
-1.54 (-4.46%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 9.26 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.46 | ||
P/tB | 2.39 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -67.94% | ||
ROE | -80.97% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 44.48% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 3.3% | ||
Cap/Sales | 4.15% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 10.66 | ||
Quick Ratio | 10.66 | ||
Altman-Z | -3.59 |